Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Presatovir in hematopoietic cell transplant recipients with RSV upper respiratory tract infection
NL-OMON44310Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Presatovir with Placebo (2 arms). Primary endpoints: Time-weighted average change in RSV nasal viral load from baseline to Day 9 and Development of lower respiratory tract complication through Day 28. Started Jan 2015; status: active, not recruiting.
02
Drugs
presatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON44310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44310.